The current findings have indicated that increased CX3CR1 levels, both in bladder tissue and peripheral blood samples, mirrored dynamic fluctuations observed in CD8+ TILs within the tumor microenvironment after OncoTherad® (MRB-CFI-1) treatment application. The gene discussed is CD8A; the disease is neoplasm.